BlackRock Investment Management LLC boosted its stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 155,151 shares of the specialty pharmaceutical company’s stock after buying an additional 1,661 shares during the period. BlackRock Investment Management LLC owned about 0.45% of AMAG Pharmaceuticals worth $3,803,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LSV Asset Management raised its position in AMAG Pharmaceuticals by 41.1% in the third quarter. LSV Asset Management now owns 379,337 shares of the specialty pharmaceutical company’s stock valued at $9,297,000 after buying an additional 110,500 shares in the last quarter. ProVise Management Group LLC purchased a new position in AMAG Pharmaceuticals during the third quarter valued at $277,000. Sei Investments Co. raised its position in AMAG Pharmaceuticals by 93.3% in the third quarter. Sei Investments Co. now owns 8,287 shares of the specialty pharmaceutical company’s stock valued at $204,000 after buying an additional 4,000 shares in the last quarter. Icon Advisers Inc. Co. purchased a new position in AMAG Pharmaceuticals during the third quarter valued at $958,000. Finally, Aperio Group LLC purchased a new position in AMAG Pharmaceuticals during the third quarter valued at $228,000.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 23.60 on Friday. AMAG Pharmaceuticals, Inc. has a one year low of $17.92 and a one year high of $36.83. The company has a market cap of $807.33 million, a P/E ratio of 54.25 and a beta of 1.01. The stock’s 50 day moving average is $30.12 and its 200-day moving average is $27.36.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.28. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The company had revenue of $143.80 million for the quarter, compared to analyst estimates of $141.65 million. During the same period last year, the firm earned $1.02 earnings per share. The firm’s revenue was up 49.5% on a year-over-year basis. Equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post $6.02 earnings per share for the current year.
Several research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $25.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, January 20th. Needham & Company LLC lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th. Janney Montgomery Scott lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 10th. Leerink Swann lowered shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $39.00 to $25.00 in a research note on Tuesday, January 10th. Finally, Raymond James Financial, Inc. reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a research note on Monday, January 9th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $34.10.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).